Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.

about

Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience.Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.

P2860

Q47342126-8988F81E-4CFC-4A96-A2C6-25A2C8C2BDC7 Q49985388-8B026AAD-1821-41DC-8291-4D94C3A89FD0

P2860

Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.

Item

http://www.wikidata.org/entity/Q38764424

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Secukinumab improves psoriasis ...... udy to evaluate direct switch.

@en

type

Item

label

Secukinumab improves psoriasis ...... udy to evaluate direct switch.

@en

prefLabel

Secukinumab improves psoriasis ...... udy to evaluate direct switch.

@en

P1476

Secukinumab improves psoriasis ...... udy to evaluate direct switch.

@en

P2093

Akimichi Morita

http://www.w3.org/2001/XMLSchema#string

Atsuyuki Igarashi

http://www.w3.org/2001/XMLSchema#string

Ayako Fujishige

http://www.w3.org/2001/XMLSchema#string

Hidemi Nakagawa

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Fujita

http://www.w3.org/2001/XMLSchema#string

Mamitaro Ohtsuki

http://www.w3.org/2001/XMLSchema#string

Masako Yamaguchi

http://www.w3.org/2001/XMLSchema#string

Rie Teshima

http://www.w3.org/2001/XMLSchema#string

Yayoi Tada

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing

Itch, disease coping strategies and quality of life in psoriasis patients.

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis.

Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting.

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.

Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.

P304

1105-1111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1346-8138.13911

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shinichi Imafuku

Yumiko Tani

P577

2017-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28543617

http://www.w3.org/2001/XMLSchema#string

P932

5655923

http://www.w3.org/2001/XMLSchema#string

Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.

about

P2860

P2860

Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932